EMA Authorised: Betmiga (Mirabegron) — Astellas Pharma Europe B.V.

View source ↗

Summary

The European Medicines Agency authorised Betmiga (mirabegron) from Astellas Pharma Europe B.V. for the treatment of overactive bladder (authorisation decision d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Betmiga (mirabegron)

Snippet

Status: Authorised. Therapeutic area: Urinary Bladder, Overactive. MAH: Astellas Pharma Europe B.V.. Decision date: 17/07/2025